DAV132: A combination therapy for digestive cancers patients
DAV132 is a first-in-class microbiome protective product. It has already been demonstrated to be safe and to effectively preserve the intestinal microbiome of healthy volunteers and patients in multiple clinical trials without impacting the clinical efficacy of concomitant treatments.
In parallel with other indications in hemato-oncology and immuno-oncology, DAV132 is being developed to prevent irinotecan-induced late-onset severe diarrhea in patients with pancreatic and colorectal cancer. Irinotecan is a widely-used chemotherapy that is found, for example, in the FOLFIRINOX and FOLFIRI chemotherapy regimens. DAV132 acts in the colon by capturing irinotecan and SN38, its toxic metabolite, to reduce its gastrointestinal toxicity and thus increase the safety and efficacy of the treatment.
DAV132 should improve the quality of life of patients and delay any discontinuation or dose reduction of chemotherapy that would reduce the patient’s chances of survival.
DAV132 Mechanism of action
- When a patient with digestive cancers is treated with irinotecan, active metabolites of irinotecan reach the colon and create direct damage to the intestinal cells, leading to inflammation of the colon and a state of dysbiosis of the intestinal microbiome. This causes severe diarrhea (grade ≥ 3) in these patients, which may lead to a reduction in the dose of irinotecan administered, or even to discontinuation of treatment. This can have a very important impact on the quality of life but also on the survival of patients, whose cancer is treated with less efficiency.
By irreversibly capturing the active residues of irinotecan in the colon, DAV132 reduces the incidence and severity of severe diarrhea in patients without affecting the antitumor efficacy of their chemotherapy. Thus, chemotherapy can be given at its optimal dose and is not interrupted prematurely, increasing patients’ chances of survival.
Why is DAV132 a unique opportunity for digestive cancers patients?
DAV132 addresses an important unmet medical need for digestive cancers patients. Metastatic pancreatic adenocarcinoma is currently considered incurable and the average life expectancy of patients is estimated to be between 7 and 11 months. In this patient population, any new treatment that improves quality of life and survival will have a strong impact on patient management. DAV132 would therefore provide a strong clinical benefit for this patient population.